Biosyent Inc. Net Assets
Biosyent Inc. net assets. Based on the latest financial reports, Biosyent Inc. (RX) has net assets worth CA$39.90 Million CAD (≈ $28.87 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$47.79 Million ≈ $34.57 Million USD) and total liabilities (CA$7.88 Million ≈ $5.70 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore RX shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$39.90 Million |
| % of Total Assets | 83.5% |
| Annual Growth Rate | 17.04% |
| 5-Year Change | 30.63% |
| 10-Year Change | 188.06% |
| Growth Volatility | 85.98 |
Net Assets of Biosyent Inc. (1997–2024)
Net assets of Biosyent Inc. from 1997 to 2024. This chart illustrates how Biosyent Inc.'s net assets have evolved over time, based on quarterly financial data. See RX net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for Biosyent Inc. (1997–2024)
The table below shows the annual net assets of Biosyent Inc. from 1997 to 2024. For live market cap and overall valuation, see Biosyent Inc. market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CA$35.00 Million ≈ $25.32 Million |
+0.70% |
| 2023-12-31 | CA$34.76 Million ≈ $25.14 Million |
+4.19% |
| 2022-12-31 | CA$33.36 Million ≈ $24.13 Million |
+5.73% |
| 2021-12-31 | CA$31.55 Million ≈ $22.83 Million |
+17.76% |
| 2020-12-31 | CA$26.80 Million ≈ $19.38 Million |
+3.88% |
| 2019-12-31 | CA$25.79 Million ≈ $18.66 Million |
-6.56% |
| 2018-12-31 | CA$27.61 Million ≈ $19.97 Million |
+24.28% |
| 2017-12-31 | CA$22.21 Million ≈ $16.07 Million |
+32.80% |
| 2016-12-31 | CA$16.73 Million ≈ $12.10 Million |
+37.65% |
| 2015-12-31 | CA$12.15 Million ≈ $8.79 Million |
+48.91% |
| 2014-12-31 | CA$8.16 Million ≈ $5.90 Million |
+68.09% |
| 2013-12-31 | CA$4.85 Million ≈ $3.51 Million |
+70.97% |
| 2012-12-31 | CA$2.84 Million ≈ $2.05 Million |
+144.24% |
| 2011-12-31 | CA$1.16 Million ≈ $840.98K |
+73.25% |
| 2010-12-31 | CA$671.02K ≈ $485.40K |
+10.54% |
| 2009-12-31 | CA$607.02K ≈ $439.11K |
-28.93% |
| 2008-12-31 | CA$854.08K ≈ $617.83K |
-23.81% |
| 2007-12-31 | CA$1.12 Million ≈ $810.93K |
-8.52% |
| 2006-12-31 | CA$1.23 Million ≈ $886.46K |
+51.02% |
| 2005-12-31 | CA$811.46K ≈ $587.00K |
+165.01% |
| 2004-12-31 | CA$306.20K ≈ $221.50K |
-49.54% |
| 2003-12-31 | CA$606.86K ≈ $438.99K |
-2.39% |
| 2002-12-31 | CA$621.73K ≈ $449.75K |
-37.25% |
| 2001-12-31 | CA$990.86K ≈ $716.77K |
+371.03% |
| 2000-12-31 | CA$210.36K ≈ $152.17K |
-64.94% |
| 1999-12-31 | CA$600.00K ≈ $434.03K |
-45.45% |
| 1998-12-31 | CA$1.10 Million ≈ $795.72K |
+120.00% |
| 1997-12-31 | CA$500.00K ≈ $361.69K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Biosyent Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3192901100.0% over the analyzed period, indicating profitable operations and earnings retention.
Biosyent Inc. Net Assets Breakdown (December 2024)
Biosyent Inc. net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CA$27.73 Million | 79.22% |
| Other Components | CA$7.27 Million | 20.78% |
| Total Equity | CA$35.00 Million | 100.00% |
Biosyent Inc. Competitors by Market Cap
The table below lists competitors of Biosyent Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Smartbroker Holding AG
XETRA:SB1
|
$133.58 Million |
|
Inclusio Sca
BR:INCLU
|
$133.60 Million |
|
Companhia Estadual de Distribuição de Energia Elétrica
SA:CEED3
|
$133.61 Million |
|
Acusensus Ltd
AU:ACE
|
$133.64 Million |
|
American Eagle Gold Corp
V:AE
|
$133.41 Million |
|
Cash Converters International
AU:CCV
|
$133.41 Million |
|
General de Alquiler de Maquinaria SA
MC:GAM
|
$133.40 Million |
|
LVMC Holdings
KO:900140
|
$133.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biosyent Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 34,759,756 to 35,003,185, a change of 243,429 (0.7%).
- Net income of 7,270,104 contributed positively to equity growth.
- Dividend payments of 2,079,691 reduced retained earnings.
- Share repurchases of 5,176,660 reduced equity.
- Other comprehensive income increased equity by 177,455.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$7.27 Million | +20.77% |
| Dividends Paid | CA$2.08 Million | -5.94% |
| Share Repurchases | CA$5.18 Million | -14.79% |
| Other Comprehensive Income | CA$177.46K | +0.51% |
| Other Changes | CA$52.22K | +0.15% |
| Total Change | CA$- | 0.70% |
Book Value vs Market Value Analysis
This analysis compares Biosyent Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.55x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 227.87x to 5.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-12-31 | CA$0.07 | CA$17.09 | x |
| 1998-12-31 | CA$0.16 | CA$17.09 | x |
| 1999-12-31 | CA$0.07 | CA$17.09 | x |
| 2000-12-31 | CA$0.02 | CA$17.09 | x |
| 2001-12-31 | CA$0.11 | CA$17.09 | x |
| 2002-12-31 | CA$0.07 | CA$17.09 | x |
| 2003-12-31 | CA$0.05 | CA$17.09 | x |
| 2004-12-31 | CA$0.02 | CA$17.09 | x |
| 2005-12-31 | CA$0.07 | CA$17.09 | x |
| 2006-12-31 | CA$0.10 | CA$17.09 | x |
| 2007-12-31 | CA$0.09 | CA$17.09 | x |
| 2008-12-31 | CA$0.07 | CA$17.09 | x |
| 2009-12-31 | CA$0.05 | CA$17.09 | x |
| 2010-12-31 | CA$0.05 | CA$17.09 | x |
| 2011-12-31 | CA$0.09 | CA$17.09 | x |
| 2012-12-31 | CA$0.20 | CA$17.09 | x |
| 2013-12-31 | CA$0.34 | CA$17.09 | x |
| 2014-12-31 | CA$0.57 | CA$17.09 | x |
| 2015-12-31 | CA$0.84 | CA$17.09 | x |
| 2016-12-31 | CA$1.15 | CA$17.09 | x |
| 2017-12-31 | CA$1.52 | CA$17.09 | x |
| 2018-12-31 | CA$1.90 | CA$17.09 | x |
| 2019-12-31 | CA$1.85 | CA$17.09 | x |
| 2020-12-31 | CA$2.05 | CA$17.09 | x |
| 2021-12-31 | CA$2.45 | CA$17.09 | x |
| 2022-12-31 | CA$2.66 | CA$17.09 | x |
| 2023-12-31 | CA$2.86 | CA$17.09 | x |
| 2024-12-31 | CA$3.08 | CA$17.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biosyent Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 20.77%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.75%
- • Asset Turnover: 0.85x
- • Equity Multiplier: 1.18x
- Recent ROE (20.77%) is above the historical average (-9.20%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | -120.00% | -85.71% | 0.64x | 2.20x | CA$-650.00K |
| 1998 | -100.00% | -157.14% | 0.44x | 1.45x | CA$-1.21 Million |
| 1999 | -83.33% | -62.50% | 0.57x | 2.33x | CA$-560.00K |
| 2000 | -192.75% | -45.70% | 0.76x | 5.58x | CA$-426.50K |
| 2001 | 78.77% | 117.20% | 0.29x | 2.28x | CA$681.41K |
| 2002 | -59.77% | -69.85% | 0.73x | 1.17x | CA$-433.80K |
| 2003 | -68.36% | -51.04% | 1.05x | 1.27x | CA$-475.56K |
| 2004 | -102.11% | -43.97% | 1.15x | 2.02x | CA$-343.28K |
| 2005 | 62.27% | 67.50% | 0.73x | 1.26x | CA$424.11K |
| 2006 | 31.27% | 25.30% | 1.04x | 1.19x | CA$260.60K |
| 2007 | -11.24% | -11.41% | 0.84x | 1.17x | CA$-238.09K |
| 2008 | -33.71% | -26.12% | 0.97x | 1.33x | CA$-373.30K |
| 2009 | -42.92% | -25.30% | 1.38x | 1.23x | CA$-321.26K |
| 2010 | 7.77% | 3.10% | 1.81x | 1.38x | CA$-14.94K |
| 2011 | 36.16% | 14.97% | 1.77x | 1.36x | CA$304.14K |
| 2012 | 54.28% | 30.68% | 1.38x | 1.29x | CA$1.26 Million |
| 2013 | 39.72% | 24.72% | 1.28x | 1.25x | CA$1.44 Million |
| 2014 | 38.65% | 25.83% | 1.15x | 1.30x | CA$2.34 Million |
| 2015 | 30.98% | 24.47% | 1.05x | 1.20x | CA$2.55 Million |
| 2016 | 25.76% | 24.05% | 0.93x | 1.15x | CA$2.64 Million |
| 2017 | 23.44% | 25.08% | 0.83x | 1.13x | CA$2.98 Million |
| 2018 | 20.67% | 26.50% | 0.69x | 1.13x | CA$2.94 Million |
| 2019 | 16.94% | 20.39% | 0.69x | 1.20x | CA$1.79 Million |
| 2020 | 14.16% | 16.99% | 0.67x | 1.25x | CA$1.12 Million |
| 2021 | 19.91% | 21.95% | 0.77x | 1.18x | CA$3.13 Million |
| 2022 | 16.36% | 19.55% | 0.69x | 1.21x | CA$2.12 Million |
| 2023 | 18.59% | 20.45% | 0.76x | 1.19x | CA$2.98 Million |
| 2024 | 20.77% | 20.75% | 0.85x | 1.18x | CA$3.77 Million |
Industry Comparison
This section compares Biosyent Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $290,226,295
- Average return on equity (ROE) among peers: -107.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biosyent Inc. (RX) | CA$39.90 Million | -120.00% | 0.20x | $133.46 Million |
| Aurora Cannabis Inc (ACB) | $662.35 Million | -259.32% | 0.64x | $259.21 Million |
| Amotiv Limited (AOV) | $795.11 Million | 0.54% | 0.21x | $576.83 Million |
| Aequus Pharmaceuticals Inc (AQS) | $-4.29 Million | 0.00% | 0.00x | $479.73K |
| Avicanna Inc (AVCN) | $3.46 Million | -426.03% | 4.09x | $10.21 Million |
| Avant Brands Inc (AVNT) | $-490.96K | 0.00% | 0.00x | $5.58 Million |
| Bausch Health Companies Inc (BHC) | $1.30 Billion | 15.07% | 0.37x | $3.10 Billion |
| CanadaBis Capital Inc (CANB) | $455.59K | -35.67% | 0.03x | $1.53 Million |
| Cannabist Company Holdings Inc (CBST) | $65.35 Million | -268.87% | 11.60x | $12.41 Million |
| Cipher Pharmaceuticals Inc (CPH) | $54.26 Million | 3.26% | 1.02x | $239.92 Million |
| Cardiol Therapeutics Inc Class A (CRDL) | $28.25 Million | -99.58% | 0.30x | $130.88 Million |
About Biosyent Inc.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form produc… Read more